Skye: Moving Weight Loss Drugs To The Next Level

Terry Chrisomalis
Investing Group Leader
(15min)

Summary

  • Skye Bioscience, Inc. interim data from phase 2 CBeyond study, using nimacimab for the treatment of patients with obesity, is expected Q2 and Q4 of 2025.
  • Experimental arm added into phase 2 CBeyond study, which is combining the use of nimacimab with Wegovy for the treatment of patients with obesity.
  • The global obesity drugs market is expected to reach $105 billion in 2030.
  • Several factors differentiate CB1 inhibitor nimacimab compared to other weight loss drugs, such as: Potential for less frequent dosing, less gastrointestinal side effects and long-term dosing for patient compliance.
  • Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More »

Modern Factory: Industrial Engineer Working on Desktop Computer in Clean Sterile Coveralls. Scientist Using a Microscope, Developing Advanced Solutions for High Tech Medical Vaccine and Gene Research

gorodenkoff/iStock via Getty Images

Skye Bioscience, Inc. (NASDAQ:SKYE) launched its phase 2 CBeyond study using its monoclonal antibody drug nimacimab for the treatment of patients with obesity. Investors should keep a close eye on this program because it

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33.50% discount price of $399 per year.

This article was written by

Terry Chrisomalis
13.46K Followers

Terry Chrisomalis is a private investor in the Biotech sector with years of experience utilizing his Applied Science background to generate long term value from Healthcare.

He is the author of the investing group Biotech Analysis Central which contains a library of 600+ Biotech investing articles, a model portfolio of 10+ small and mid-cap stocks with deep analysis for each, live chat, and a range of analysis and news reports to help Healthcare investors make informed decisions.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

About SKYE Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on SKYE

Related Stocks

SymbolLast Price% Chg
SKYE
--
Compare

Trending Analysis

Trending News